NYSE: SYK
STRYKER CORPCIK 0000310764 · Health Care · SIC 3841 · Surgical & Medical Instruments
Each report below shows a 3-bullet preview. Free accounts read 3 full reports a month — narrative summary, section diffs, and EDGAR-cited quotes.
Sign up freeWant to see a complete report first? Today's free report (VG 10-Q) is open in full — no account needed.
Summary not yet generated.
Stryker reports 9.0% organic sales growth and 17.9% adjusted EPS growth in Q2 2026
4 material changes detected. Sign up free to read the summary.
Partner
Trade SYK commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Stryker reports 11.2% sales growth for 2025, reorganizes segments around Mako robotics
5 material changes detected. Sign up free to read the summary.
Stryker CAO William Berry to retire Sept 1; VP Controller Emily Baculik promoted to succeed
2 material changes detected. Sign up free to read the summary.
Stryker Q1 sales +2.6%, adj. EPS -8.5% as March cybersecurity breach disrupts operations
5 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Stryker Q1 adjusted EPS falls 8.5% to $2.60 despite 2.6% sales growth; cyber incident cited
5 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Jul 31, 2026 (period ending Jun 30, 2026). SEC XBRL (companyfacts) — not generated by the model.
Consolidated Statements of Operations (Unaudited)
| Description | Q2 ended Jun 30, 2026 | Q1 ended Mar 31, 2026 |
|---|---|---|
| Revenue: | ||
| Total revenue / net sales | 6,589 | 6,020 |
| Cost of revenue / cost of sales | 2,091 | 2,210 |
| Gross profit | 4,498 | 3,810 |
| Operating expenses: | ||
| Research and development | 434.0 | 413.0 |
| Selling, general and administrative | 2,229 | 2,281 |
| Total operating expenses | 2,839 | 2,874 |
| Operating income | 1,659 | 936.0 |
| Interest expense | 141.0 | 148.0 |
| Other income/(expense), net | 46.0 | 62.0 |
| Income before income taxes | 1,564 | 850.0 |
| Income tax expense/(benefit) | 288.0 | 105.0 |
| Net income | 1,276 | 745.0 |
| Basic earnings per share | 3.32 | 1.95 |
| Diluted earnings per share | 3.30 | 1.93 |
Consolidated Balance Sheets (Unaudited)
| Description | Jun 30, 2026 | Mar 31, 2026 |
|---|---|---|
| Current assets: | ||
| Cash and equivalents | 3,391 | 2,878 |
| Short-term investments | 85.0 | 87.0 |
| Accounts receivable, net | 3,743 | 3,571 |
| Inventories | 3,615 | 3,511 |
| Prepaid expenses and other current assets | 1,678 | 1,383 |
| Other current assets | 1,906 | 1,908 |
| Total current assets | 14,418 | 13,338 |
| Property, plant and equipment, net | 3,958 | 3,887 |
| Operating lease right-of-use assets, net | 521.0 | 529.0 |
| Identifiable intangible assets, net | 5,742 | 5,516 |
| Goodwill | 19,584 | 19,188 |
| Deferred income taxes and other assets | 994.0 | 1,193 |
| Other long-term assets | 2,713 | 2,640 |
| TOTAL ASSETS | 47,930 | 46,291 |
| Current liabilities: | ||
| Current portion of long-term debt | 750.0 | 499.0 |
| Current portion of operating lease liabilities | 159.0 | 161.0 |
| Accrued liabilities | 2,604 | 2,526 |
| Income taxes payable | 224.0 | 476.0 |
| Other current liabilities | 2,947 | 2,653 |
| Total current liabilities | 6,684 | 6,315 |
| Long-term debt | 14,192 | 14,224 |
| Operating lease liabilities | 345.0 | 350.0 |
| Deferred income taxes and other liabilities | 2,660 | 2,370 |
| Total liabilities | 23,942 | 23,312 |
| Shareholders' equity: | ||
| Capital in excess of stated value | 2,711 | 2,646 |
| Accumulated other comprehensive income (loss) | (576.0) | (583.0) |
| Retained earnings (deficit) | 21,815 | 20,878 |
| Total shareholders' equity | 23,988 | 22,979 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 47,930 | 46,291 |
Consolidated Statements of Cash Flows (Unaudited)
| Description | Six months ended Jun 30, 2026 | Q1 ended Mar 31, 2026 |
|---|---|---|
| Operating Activities: | ||
| Net cash from operating activities | 1,842 | 581.0 |
| Investing Activities: | ||
| Net cash from investing activities | (824.0) | (185.0) |
| Financing Activities: | ||
| Net cash from financing activities | (1,605) | (1,510) |
| Net increase/(decrease) in cash | (620.0) | (1,133) |
Amounts in millions USD; EPS as reported. Line labels are presentation-friendly mappings of filer XBRL tags — not a re-audit of the full statements. Use EDGAR for interactive notes and detail. Interactive statements & notes on EDGAR ↗